CN102872117B - Application of Houttuynoid D in preparing medicine for treating gastric cancer - Google Patents
Application of Houttuynoid D in preparing medicine for treating gastric cancer Download PDFInfo
- Publication number
- CN102872117B CN102872117B CN 201210419406 CN201210419406A CN102872117B CN 102872117 B CN102872117 B CN 102872117B CN 201210419406 CN201210419406 CN 201210419406 CN 201210419406 A CN201210419406 A CN 201210419406A CN 102872117 B CN102872117 B CN 102872117B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- gastric cancer
- application
- preparing
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses application of Houttuynoid D in preparing a medicament for treating gastric cancer, and belongs to the technical field of new use of medicaments. Houttuynoid D is found to have an obvious inbibitional effect on the growth of human gastric cancer cell lines HGC-27, MGC-803, BGC-823 and SGC-7901 through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid D can be used for preparing the anti-gastric cancer medicament and has excellent prospects in development and application. The use of Houttuynoid D in preparing the medicament for treating the gastric cancer involved in the invention is disclosed for the first time; the framework type of Houttuynoid D is a brand new framework type; and Houttuynoid D has an unexpectedly high inhibition activity for gastric cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid D, relate in particular to the application of Houttuynoid D in the anti-gastric cancer medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid D that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) new framework compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes in preparation treatment gastric cancer medicine that the present invention relates to, because framework types belongs to brand-new framework types, and its inhibition for stomach cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for Prevention and Treatment of Stomach Cancer simultaneously and obviously have obvious improvement.
Summary of the invention
The invention provides the application of compound H outtuynoid D in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid D in the anti-gastric cancer medicine of preparation, and the structural formula of Houttuynoid D is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation the growth of the human stomach cancer cell line HGC-27 of Houttuynoid D, MGC-803, BGC-823 and SGC-7901 also has significant inhibitory effect, suppresses the IC of this 4 strain cell growth
50Value is respectively 1.02 ± 0.39 μ M, 2.41 ± 0.59 μ M, 3.83 ± 0.79 μ M and 4.49 ± 1.04 μ M.Therefore, Houttuynoid D can have the excellent development application prospect for the preparation of anti-gastric cancer medicine.
Belong to open first for the purposes of the Houttuynoid D that the present invention relates in preparation treatment gastric cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for stomach cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for Prevention and Treatment of Stomach Cancer simultaneously and obviously have obvious improvement.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid D involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid D tablet involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid D capsule involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of the human stomach cancer cell line of mtt assay assessing compound Houttuynoid D
1. method: the cell that is in the growth logarithmic (log) phase: human stomach cancer cell line HGC-27, MGC-803, BGC-823 and SGC-7901(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Cell culture 24 h inhale adherent back and go original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid D of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, inhale along culture fluid top then and remove 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570 nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: the growth of the human stomach cancer cell line HGC-27 of Houttuynoid D, MGC-803, BGC-823 and SGC-7901 has significant inhibitory effect.This chemical compound suppresses the IC of human stomach cancer cell line HGC-27, MGC-803, BGC-823 and SGC-7901 growth
50Value is respectively: 1.02 ± 0.39 μ M, 2.41 ± 0.59 μ M, 3.83 ± 0.79 μ M and 4.49 ± 1.04 μ M.
Shown that by above-described embodiment the growth of the human stomach cancer cell line HGC-27 of Houttuynoid D of the present invention, MGC-803, BGC-823 and SGC-7901 has the good restraining effect.Prove that thus Houttuynoid D of the present invention has anti-gastric cancer activity, can be for the preparation of anti-gastric cancer medicine.
Claims (1)
1.Houttuynoid the application of D in preparation treatment gastric cancer medicine, described compound H outtuynoid D structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419406 CN102872117B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in preparing medicine for treating gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419406 CN102872117B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in preparing medicine for treating gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872117A CN102872117A (en) | 2013-01-16 |
| CN102872117B true CN102872117B (en) | 2013-07-17 |
Family
ID=47473788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419406 Expired - Fee Related CN102872117B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in preparing medicine for treating gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872117B (en) |
-
2012
- 2012-10-27 CN CN 201210419406 patent/CN102872117B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872117A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861065B (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872117B (en) | Application of Houttuynoid D in preparing medicine for treating gastric cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872081B (en) | Application of Houttuynoid C in drugs for treating gastric cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872110B (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872129B (en) | Application of Houttuynoid E in drug for treating endometrial cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102861064B (en) | Application of Houttuynoid E in preparing medicine for treating laryngocarcinoma | |
| CN102872135B (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU DINGBANG BIOMASS ENERGY MACHINERY CO., LTD Free format text: FORMER OWNER: WU JUNHUA Effective date: 20131209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 213351 CHANGZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131209 Address after: 213351 Jiangsu city of Changzhou province Liyang Liyang Town of Wuhu Shanghai Road No. 168 Patentee after: Jiangsu Dingbang Biomass Energy Machinery Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |